Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
abrdn Life Sciences InvestorsHQL -2.56%51 EV-to-OCF is 16.87 as of Aug. 20, 2026, which is 2% above its 10-year median of 16.54. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,504 Asset Management companies, abrdn Life Sciences Investors ranks worse than 72.81% on this metric.
The historical rank and industry rank for abrdn Life Sciences Investors's EV-to-OCF or its related term are showing as below:
HQL'
s EV-to-OCF Range Over the Past 10 Years
Min: 15.26 Med: 16.54 Max: 21.93
Current: 16.87
During the past 9 years, the highest EV-to-OCF of abrdn Life Sciences Investors was 21.93. The lowest was 15.26. And the median was 16.54.
HQL's EV-to-OCF is ranked worse than 72.81% of 1504
companies
in the Asset Management industry
Industry Median: 5.86
vs HQL: 16.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
abrdn Life Sciences Investors (NYSE:HQL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
abrdn Life Sciences Investors's PE Ratio (TTM) for today is calculated as:
abrdn Life Sciences Investors's share price for today is $22.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $6.638.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
abrdn Life Sciences Investors EV-to-OCF Related Terms
abrdn Life Sciences Investors EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, abrdn Life Sciences Investors's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors EV-to-OCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's EV-to-OCF falls into.
abrdn Life Sciences Investors's current Enterprise Value is $671.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $39.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a EV-to-OCF of 16.87 as of Aug. 20, 2026. This is near median its historical median of 16.54. Over the past decade, abrdn Life Sciences Investors' EV-to-OCF has ranged from 15.26 to 21.93. According to the industry distribution chart, abrdn Life Sciences Investors ranks #1095 out of 1504 companies in the Asset Management industry, placing it in the top 72.8%.
Is abrdn Life Sciences Investors' EV-to-OCF too high?
abrdn Life Sciences Investors' current EV-to-OCF of 16.87 is near median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 15.26 to a high of 21.93. The Asset Management industry median EV-to-OCF is 5.86. abrdn Life Sciences Investors' value of 16.87 is 187.9% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #1095 out of 1504 companies in the Asset Management industry, which is below the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' EV-to-OCF compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #1095 out of 1504 companies for EV-to-OCF. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median EV-to-OCF is 5.86. abrdn Life Sciences Investors' value of 16.87 is 187.9% above this benchmark. Historically, abrdn Life Sciences Investors' own EV-to-OCF has ranged from 15.26 to 21.93 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 5.86, abrdn Life Sciences Investors has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for an Asset Management company?
The median EV-to-OCF among Asset Management companies is 5.86, based on 1,504 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current EV-to-OCF of 16.87 is 187.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median EV-to-OCF is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current EV-to-OCF is 16.87, which is near median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.09 — trading 64.4% below its estimated fair value. The current EV-to-OCF is 16.87, which is near median its 10-year median of 16.54 and 187.9% above the Asset Management industry median of 5.86. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current EV-to-OCF is 16.87 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.09 is trading 64.4% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
EV-to-OCF: 16.87 (near median its 10-year median of 16.54)
GF Value™: $62.01 vs. price of $22.09 (64.4% below fair value)
Industry Position: 187.9% above the Asset Management median (#1095 of 1504)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
